Cologuard is covered for a majority of patients*

>94^% No out-of-pocket costs^*

Nationwide, >94% of all Cologuard patients have no out-of-pocket costs for screening.*

45-49

Coverage for patients aged 45-49 years

Currently, ~74% of Cologuard patients aged 45-49 years have had no out-of-pocket costs.*

Many national and regional payers have begun updating their medical policies to begin coverage of colorectal cancer (CRC) screening at age 45.

Our team of specialists can help patients contact their insurer and ask the right questions. If your patients have questions, they can call us at 1-844-870-8870.

See study results with previously noncompliant patients

^*Exact Sciences estimate based on historical patient billing as of October 1, 2019. Rate of coverage varies by state and region. Exceptions for coverage may apply; only your patients' insurers can confirm how Cologuard would be covered.

Indication and Important Risk Information Cologuard is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA) and should be followed by diagnostic colonoscopy. Cologuard is indicated to screen adults of either sex, 45 years or older, who are at typical average risk for CRC. Cologuard is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Cologuard is not for high-risk individuals, including patients with a personal history of colorectal cancer and adenomas; have had a positive result from another colorectal cancer screening method within the last 6 months; have been diagnosed with a condition associated with high risk for colorectal cancer such as IBD, chronic ulcerative colitis, Crohn’s disease; or have a family history of colorectal cancer, or certain hereditary syndromes.

Positive Cologuard results should be referred to diagnostic colonoscopy. A negative Cologuard test result does not guarantee absence of cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient.

False positives and false negatives do occur. In a clinical study, 13% of patients without colorectal cancer or advanced adenomas received a positive result (false positive) and 8% of patients with cancer received a negative result (false negative). The clinical validation study was conducted in patients 50 years of age and older. Cologuard performance in patients ages 45 to 49 years was estimated by sub-group analysis of near-age groups.

Cologuard performance when used for repeat testing has not been evaluated or established. Rx only.

EXACT SCIENCES CORPORATION | 441 Charmany Drive | Madison, WI 53719

Cologuard is a registered trademark of Exact Sciences Corporation in the U.S. and other countries. EpicCare^® and EpicCare Link™ are trademarks of Epic Systems Corporation.